Early Drug Development: Identify And Mitigate Absorption Risks With PBPK Models

Getting new drugs to patients rapidly and efficiently is a top priority for pharmaceutical companies. However, many early drug candidates struggle to be absorbed by the body, making it difficult to achieve the desired effects. This can lead to delays and higher costs in preclinical and clinical trials.

There's a powerful tool called PBPK modeling that can help overcome this hurdle. PBPK software, like GastroPlus® platform from Simulations Plus, can predict how the body will absorb a drug. By combining this technology with lab tests, scientists can:

1. Identify potential problems with absorption early on.
2. Assess the potential for solubility enhancing formulations such as salts, cocrystals, or amorphous solid dispersions.
3. Design and optimize preclinical and clinical studies with respect to dose, prandial state, or gastric pH modification.

This webinar shows how PBPK modeling, along with Lonza's expertise in drug solubility and testing tools, can help you identify and address absorption issues early in drug development. This can save you time, money, and resources by reducing the need to reformulate drugs or repeat trials.

Learn:

• How PBPK modeling can predict absorption problems and suggest solutions for new drugs.
• How PBPK modeling and lab tests can help you choose the best form and formulation for your drug.
• How factors like a drug's solubility, permeability, and how quickly it dissolves can affect absorption, food interactions, and other issues.